BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX:DDD - News) today announced positive preliminary results from pilot bioavailability testing of its refined 24-hour CDT-based ondansetron tablets. The Company also reported that it will no longer continue the development of a 12-hour CDT-based phenylepherine formulation.
